Roche Fuzeon (T-20) NDA
Executive Summary
Roche and Trimeris file NDA for HIV fusion inhibitor Fuzeon (T-20/enfuvirtide) Sept. 17. The companies are establishing a 1,200-patient access program in anticipation of supply constraints (1"The Pink Sheet" Aug. 5, In Brief)...